Importantly, the addition of GSK-J4 significantly inhibited colony formation from primary cells of myeloid malignancy patients with ASXL1 mutations (Figure 7F and Supplemental Figure 7H), whereas a minimal effect of GSK-J4 was observed in the primary cells of a myeloid malignancy patient without ASXL1 mutation (Supplemental Figure 7I). This evidence concerns the gene ASXL1 and myeloid neoplasm.